Treatment of chronic myeloid leukemia when imatinib fails

Introduction: Imatinib failure represents a major clinical challenge in the management of chronic myeloid leukemia. Areas covered: Definition of failure, its causes, the various approaches to the treatment of imatinib failure such as imatinib dose escalation, second-generation tyrosine kinase inhibi...

Full description

Saved in:
Bibliographic Details
Main Authors: Hehlmann, Rüdiger (Author) , Jung-Munkwitz, Susanne (Author) , Saußele, Susanne (Author)
Format: Article (Journal)
Language:English
Published: 13 Jan 2011
In: Expert opinion on pharmacotherapy
Year: 2011, Volume: 12, Issue: 2, Pages: 269-283
ISSN:1744-7666
DOI:10.1517/14656566.2011.533169
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1517/14656566.2011.533169
Get full text
Author Notes:Rüdiger Hehlmann, Susanne Jung-Munkwitz, Susanne Saußele
Description
Summary:Introduction: Imatinib failure represents a major clinical challenge in the management of chronic myeloid leukemia. Areas covered: Definition of failure, its causes, the various approaches to the treatment of imatinib failure such as imatinib dose escalation, second-generation tyrosine kinase inhibitors and stem cell transplantation, and monitoring of residual disease are covered in this review. Selected investigational agents and the management of blast crisis are also reviewed. After reading the review the reader will understand how to manage imatinib failure. Expert opinion: Imatinib failure can be managed in most cases by a careful appraisal of its causes and a rational selection of treatment options.
Item Description:Gesehen am 28.09.2022
Physical Description:Online Resource
ISSN:1744-7666
DOI:10.1517/14656566.2011.533169